Agilent Technologies is partnering with Seoul National University to put together a new research center that it says will support SNU's College of Pharmacy's New Drug Development Center. Agilent and the College of Pharmacy signed an MOU stating plans jointly to conduct drug metabolism studies, research and develop new compounds, assess drug toxicity and remedial effects as well as pharmacokinetics, and conduct clinical tests for drugs.
Agilent says it will provide bio-analytical instruments and expertise in pharmaceutical drug testing and multi-omic biological systems to the College of Pharmacy as part of the deal. The firm adds that it will also be using the new center as its reference site for drug development. SNU's New Drug Development Center, where the new center will be located, is a six-story multi-purpose research center for drug development that SNU says houses facilities for analysis, efficacy testing, and medicinal ingredient research.
“We have been leading Korea’s pharmaceutical industry through the strategic use of technology and driving the development of new drugs,” Bong-Jin Lee, Ph.D., dean of the College of Pharmacy, said in a statement. “As we prepare students for the future, we will push the frontiers of drug development by expanding our research facilities, producing outstanding research, and leading the development of technology. We are pleased to collaborate with Agilent, as our scientists and researchers require the latest, most sophisticated instruments for their work.”